Loading...
Short communication: management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: a survey of practice.
Haslett, Kate De Ruysscher, D Dziadziuszko, R Guckenberger, M Pechoux, C Nestle, U Slotman, B
Haslett, Kate
De Ruysscher, D
Dziadziuszko, R
Guckenberger, M
Pechoux, C
Nestle, U
Slotman, B
Citations
Altmetric:
Abstract
The results of the randomized phase 3 CREST trial evaluating the use of thoracic radiotherapy for extensive-stage small-cell lung cancer (ES-SCLC) were published in the Lancet in 2015. The primary endpoint (10% overall survival difference at 1-year) was not achieved, but there was significant improvement in 2-year overall survival (13% vs 3%; p = 0.004) and low toxicity rates, suggesting thoracic radiotherapy should be considered for ES-SCLC patients who respond to chemotherapy. Questions have been raised as to whether these results will lead to a change in practice.
Description
Date
2018-08-30
Publisher
Collections
Files
Keywords
Type
Article
Citation
Short communication: management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: a survey of practice. 2018, 17: 18-22 Cancer Treat Res Commun